Hypha Labs

Pioneering the Production of Functional Mushrooms

[Hypha Labs @Hypha_Labs]

Citing a recent study published in the Annals of Internal Medicine and reported today on https://t.co/KdQac6eGWd, “Psilocybin mushrooms are now the 2nd most frequently used substance in the country, behind only cannabis,” said Joshua Black, co-lead author of the cited study and senior scientist at Rocky Mountain Poison and Drug Safety, a division of Denver Health. Mental and physical health, along with chronic pain treatment appeared to be major drivers of use.

[Hypha Labs @Hypha_Labs]

The power of mushrooms continues to be unveiled.
Psilocybin for disorders of consciousness: A case-report study - For the full report visit https://t.co/nYPMdbu0B9

Abstract
Objective
With very few treatments available, post-comatose disorders of consciousness (DoC) pose one of the hardest challenges in modern neurology. Following promising clinical trial results in psychiatry, and a deepening understanding of their brain mechanisms, psychedelics have been suggested as a novel therapeutic drug for DoC patients, given that they increase the entropy or complexity of spontaneous activity in healthy participants. However, no attempts have been so far performed in patients with DoC.
Methods
In this case report, we describe the first-ever administration of psilocybin, a classic psychedelic (i.e., agonist at the 5-HT2A receptor), to a patient in a minimally conscious state plus. We report the behavioural effects and changes in neurophysiology measured with EEG.
Results
We report no increase in overt behavioural repertoire with validated scales, yet new spontaneous behaviour not previously seen, and increased brain complexity, as measured by the Lempel-Ziv complexity index, with changes in the underlying periodic rhythms.
Conclusions
This study contributes to future investigations exploring the use of psychedelics in DoC, enriching the discussion surrounding the role of psychedelics in medicine, and the link between brain complexity and consciousness.

[Hypha Labs @Hypha_Labs]

Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade. LAS VEGAS, NV / ACCESS Newswire / May 1, 2025 /

Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls(TM) suite of products, is pleased to announce the acquisition of a cutting-edge High-Performance Liquid Chromatography (HPLC) analytic machine, further enhancing our capabilities in precision measurement and analysis.

In a strategic partnership with Lucidity Systems, the Company is also thrilled to announce early access to their newly released variable loop autosampler upgrade, designed to elevate the performance of its already advanced machine.
This collaboration allows Hypha Labs to leverage Lucidity Systems' innovative technology, enabling the Company to exercise its advanced methods and techniques at a higher potency resolution. The new autosampler upgrade will significantly enhance the Company's ability to conduct low granular resolution measurements, which is crucial for its ongoing research and development efforts.

With this upgrade, Hypha Labs will be able to separate peaks more effectively and measure the potencies of the Micropearl active compounds with unprecedented accuracy. This advancement will provide the Company with deeper insights, allowing Hypha Labs to fine tune its research more precisely with the revolutionary Mushroom Accelerator machine. This is a win for customers, allowing the Company to produce a more consistent and highly valued product outcome.

[Hypha Labs @Hypha_Labs]

The Future of Mental Health Treatment: Psychedelic Mushrooms on the Rise https://t.co/b3h4Su0Ewe

[Hypha Labs @Hypha_Labs]

New Mexico joins Colorado and Oregon in decriminalizing the use of psilocybin for medicinal use and our newest 3d printers are preparing to create more bioreactors. Readying for market OTCBQ:FUNI

[Hypha Labs @Hypha_Labs]

Working inside the Clean Room at Hypha Labs

[Hypha Labs @Hypha_Labs]

Mushroom accelerator bioreactors at work at Hypha Labs.

[Hypha Labs @Hypha_Labs]

Progress...

[Hypha Labs @Hypha_Labs]

Testing yields of mushroom micropearls grown in Hypha Labs Micropearl Machine - bioreactor outputs shown inside Hypha labs clean room.

[Hypha Labs @Hypha_Labs]

@KevinSupermasve @smallcapvoice fyi...Hypha Laboratories Reports Significant Breakthrough for MicroPearls(TM) Yields | Newswire

[Hypha Labs @Hypha_Labs]

@KevinSupermasve @smallcapvoice Absolutely

[Hypha Labs @Hypha_Labs]

Snapshot of the Micropearl Machine app interface. In just 8 days, consumers will be able to harvest Oyster micropearls inside Hypha Labs proprietary mycelium blend cartridge to enjoy. Oyster pearls are just one variety of mushroom micropearls that will be made available upon completion of Hypha Labs final R&D phase.

[Hypha Labs @Hypha_Labs]

@PsychedelicSci Name of event please?

[Hypha Labs @Hypha_Labs]

Making Micropearls at home with Hypha Labs' Micropearl Lion's Mane cartridge